University of Texas System

Georg-august-universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin

Georg-august-universitat Gottingen Stiftung Offentlichen Rechts, Universitatsmedizin

Björn Tampe

Raghu Kalluri

Elisabeth Zeisberg

Désiree Tampe

Michael Zeisberg

Gerhard Anton Mueller

Gerd Hasenfuss

Karl Toischer

Claudius Jacobshagen

Miriam Puls

The present disclosure is directed to novel therapeutic approaches for the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of an organ. Specifically disclosed are agents for use in increasing homodimer-formation of ARNT in an organ in the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of said organ, as further defined in the claims. In embodiments, said agent may be (i) an inhibitor of protein phosphatase 2A (PP2A) activity, (ii) an inhibitor of the transcriptional repressor complex FKBP12/YY1, or (iii) an expression construct, which is capable of over-expressing ARNT in said organ, as well as combinations of (i), (ii), and/or (iii).

Prevention or treatment of chronic organ injury

Growing community of inventors

Goettingen, Germany

Björn Tampe